Wortmannin exhibits anticancer activity in oral cancer cell line by targeting PI3K, AKT and mTOR pathway.

Objective: Although the molecular mechanism by which wortmannin exerts its anticancer properties in solid tumors is not fully understood, particularly in the context of oral cancer where research is scarce, this study seeks to explore how wortmannin disrupts the PI3K pathway, consequently affecting the proliferation and apoptosis of human oral cancer cells. Materials and Methods: experiments examined Viability Assay, apoptosis, cell cycle, Reactive Oxygen Species ROS and MMP levels, and gene expression. Results: expression increased. Conclusion: research are needed.